Research at The Clatterbridge Cancer Centre involves high-level collaborations and partnerships with academic and NHS organisations to enhance our understanding of cancer and to improve outcomes for patients.
This includes working as a collaborator within Liverpool Experimental Cancer Medicine Centre (ECMC); being Associate Partner in a Biomedical Research Centre (BRC); and being part of Liverpool Clinical Research Facility (CRF).
Biomedical Research Centre
CCC is Associate Partner in a NIHR Biomedical Research Centre (BRC) with The Royal Marsden, in London, and the Institute of Cancer Research.
CCC is working in five fields for the BRC:
- Immunotherapeutics
- Precision Diagnostics and Cancer Evolution
- Advanced Technologies for Cure
- Precision Therapeutics and Cancer Treatment Effects
- Survivorship.
Professor Nagesh Kalakonda is CCC’s academic lead within the BRC.
Clinical Research Facility
The NIHR Liverpool Clinical Research Facility (CRF) is a collaboration between CCC, Liverpool University Hospital NHS Foundation Trust (LUHFT) and Liverpool Heart and Chest Hospital (LHCH) to raise the level of early phase research.
The collaboration and was launched in November 2022 and has created shared training opportunities for nursing and medical staff involved in early phase research.
Experimental Cancer Medicine Centre
The Liverpool Experimental Cancer Medicine Centre (ECMC) is a collaboration between CCC, Liverpool Clinical Trials Centre and scientists and researchers at The University of Liverpool.
It is part of a network of 17 ECMCs across the UK, funded by Cancer Research UK, which deliver clinical trials of promising new treatments.
Professor Dan Palmer is the academic lead of Liverpool ECMC.
